07:26 AM EDT, 03/28/2025 (MT Newswires) -- Eli Lilly's ( LLY ) early Alzheimer's drug, Kisunla, should not be granted marketing authorization, according to a recommendation by the European Medicines Agency's Committee for Medicinal Products for Human Use.

"The committee considered that the benefits of this medicine were not large enough to outweigh the risk of potentially fatal events due to amyloid-related imaging abnormalities (ARIA), involving swelling and potential bleedings in the brain," the CHMP said in a statement.

Eli Lilly ( LLY ) did not immediately reply to a request for comment.